NL301139I2 - Selumetinibwaterstofsulfaat, desgewenst in watervrije vorm of in de vorm van een solvaat - Google Patents
Selumetinibwaterstofsulfaat, desgewenst in watervrije vorm of in de vorm van een solvaatInfo
- Publication number
- NL301139I2 NL301139I2 NL301139C NL301139C NL301139I2 NL 301139 I2 NL301139 I2 NL 301139I2 NL 301139 C NL301139 C NL 301139C NL 301139 C NL301139 C NL 301139C NL 301139 I2 NL301139 I2 NL 301139I2
- Authority
- NL
- Netherlands
- Prior art keywords
- selumetinib
- anhydrous
- optionally
- solvate form
- hydrogen sulphate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75278105P | 2005-12-21 | 2005-12-21 | |
| PCT/US2006/061895 WO2007076245A2 (en) | 2005-12-21 | 2006-12-12 | Novel hydrogen sulfate salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301139I1 NL301139I1 (nl) | 2021-11-03 |
| NL301139I2 true NL301139I2 (nl) | 2022-02-22 |
Family
ID=38218759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301139C NL301139I2 (nl) | 2005-12-21 | 2021-10-27 | Selumetinibwaterstofsulfaat, desgewenst in watervrije vorm of in de vorm van een solvaat |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US20100016393A1 (nl) |
| EP (1) | EP1968948B1 (nl) |
| JP (1) | JP5127723B2 (nl) |
| KR (1) | KR101361460B1 (nl) |
| CN (2) | CN102329270A (nl) |
| AR (1) | AR058696A1 (nl) |
| AU (1) | AU2006330759B2 (nl) |
| BR (1) | BRPI0620091A2 (nl) |
| CA (1) | CA2634149C (nl) |
| CY (1) | CY1114303T1 (nl) |
| DK (1) | DK1968948T3 (nl) |
| EC (1) | ECSP088597A (nl) |
| ES (1) | ES2421746T3 (nl) |
| FR (1) | FR21C1051I2 (nl) |
| HK (1) | HK1124043A1 (nl) |
| HR (1) | HRP20130663T1 (nl) |
| HU (1) | HUS2100046I1 (nl) |
| IL (1) | IL192224A (nl) |
| LT (1) | LTC1968948I2 (nl) |
| MX (1) | MX2008008298A (nl) |
| MY (1) | MY157733A (nl) |
| NL (1) | NL301139I2 (nl) |
| NZ (1) | NZ569792A (nl) |
| PL (1) | PL1968948T3 (nl) |
| PT (1) | PT1968948E (nl) |
| RS (1) | RS52843B (nl) |
| SI (1) | SI1968948T1 (nl) |
| TW (1) | TWI405756B (nl) |
| UA (1) | UA93531C2 (nl) |
| WO (1) | WO2007076245A2 (nl) |
| ZA (1) | ZA200805705B (nl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2130536B1 (en) | 2002-03-13 | 2013-05-08 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
| TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
| JP2011506420A (ja) * | 2007-12-12 | 2011-03-03 | アストラゼネカ アクチボラグ | Ｍｅｋ阻害剤及びオーロラキナーゼ阻害剤１８８を含んでなる組合せ |
| SA109300195B1 (ar) * | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
| WO2011095807A1 (en) | 2010-02-07 | 2011-08-11 | Astrazeneca Ab | Combinations of mek and hh inhibitors |
| WO2012145503A1 (en) * | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
| EP3608340A1 (en) | 2011-11-23 | 2020-02-12 | Medlmmune, LLC | Binding molecules specific for her3 and uses thereof |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| PL3702351T3 (pl) * | 2012-10-19 | 2024-04-02 | Array Biopharma, Inc. | Formulacja zawierająca inhibitor mek |
| ES2642201T3 (es) | 2013-03-06 | 2017-11-15 | Astrazeneca Ab | Inhibidores de quinazolina de formas mutantes de activación del receptor del factor de crecimiento epidérmico |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| CN105566327A (zh) * | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
| EP3355923B1 (en) | 2015-10-01 | 2022-02-23 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma |
| US9844540B2 (en) | 2015-10-06 | 2017-12-19 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
| WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
| WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
| EP3712133A4 (en) * | 2017-11-14 | 2021-05-12 | Shenzhen TargetRx, Inc. | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION WITH IT |
| TWI791916B (zh) * | 2018-10-31 | 2023-02-11 | 法商施維雅藥廠 | Bcl-2抑制劑的新穎鹽、相關的結晶形式、其製備方法及包含其之醫藥組合物 |
| US20220405506A1 (en) * | 2021-06-22 | 2022-12-22 | Intrinsic Innovation Llc | Systems and methods for a vision guided end effector |
| WO2023238000A1 (en) * | 2022-06-06 | 2023-12-14 | Glenmark Life Sciences Limited | Process for preparation of selumetinib and salts thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
| KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
| PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
| US6303636B1 (en) | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| EP2130536B1 (en) * | 2002-03-13 | 2013-05-08 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| EP1913942B1 (en) | 2003-09-09 | 2009-11-11 | Biogen Idec International GmbH | The use of fumaric acid derivatives for inhibition of PGF-induced thymidine uptake of bronchial smooth muscle cells and for inhibition of bronchial smooth cells proliferation |
| TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
| SA109300195B1 (ar) * | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
-
2006
- 2006-12-04 TW TW095144927A patent/TWI405756B/zh active
- 2006-12-12 UA UAA200808839A patent/UA93531C2/ru unknown
- 2006-12-12 WO PCT/US2006/061895 patent/WO2007076245A2/en active Application Filing
- 2006-12-12 MX MX2008008298A patent/MX2008008298A/es active IP Right Grant
- 2006-12-12 DK DK06840192.6T patent/DK1968948T3/da active
- 2006-12-12 US US12/097,942 patent/US20100016393A1/en not_active Abandoned
- 2006-12-12 RS RS20130295A patent/RS52843B/en unknown
- 2006-12-12 PL PL06840192T patent/PL1968948T3/pl unknown
- 2006-12-12 MY MYPI20082207A patent/MY157733A/en unknown
- 2006-12-12 JP JP2008547679A patent/JP5127723B2/ja active Active
- 2006-12-12 CN CN2011102355739A patent/CN102329270A/zh active Pending
- 2006-12-12 EP EP06840192.6A patent/EP1968948B1/en active Active
- 2006-12-12 PT PT68401926T patent/PT1968948E/pt unknown
- 2006-12-12 KR KR1020087017543A patent/KR101361460B1/ko active Protection Beyond IP Right Term
- 2006-12-12 SI SI200631619T patent/SI1968948T1/sl unknown
- 2006-12-12 CN CN2006800514795A patent/CN101360718B/zh active Active
- 2006-12-12 ES ES06840192T patent/ES2421746T3/es active Active
- 2006-12-12 NZ NZ569792A patent/NZ569792A/en unknown
- 2006-12-12 CA CA2634149A patent/CA2634149C/en active Active
- 2006-12-12 BR BRPI0620091-5A patent/BRPI0620091A2/pt not_active Application Discontinuation
- 2006-12-12 AU AU2006330759A patent/AU2006330759B2/en active Active
- 2006-12-20 AR ARP060105662A patent/AR058696A1/es not_active Application Discontinuation
-
2008
- 2008-06-16 IL IL192224A patent/IL192224A/en active IP Right Grant
- 2008-06-30 ZA ZA2008/05705A patent/ZA200805705B/en unknown
- 2008-07-02 EC EC2008008597A patent/ECSP088597A/es unknown
-
2009
- 2009-02-16 HK HK09101437.0A patent/HK1124043A1/xx unknown
-
2012
- 2012-05-03 US US13/463,499 patent/US9156795B2/en active Active
-
2013
- 2013-07-11 HR HRP20130663TT patent/HRP20130663T1/hr unknown
- 2013-07-11 CY CY20131100590T patent/CY1114303T1/el unknown
-
2014
- 2014-01-10 US US14/152,766 patent/US20140221443A1/en not_active Abandoned
-
2015
- 2015-04-28 US US14/698,151 patent/US9562017B2/en active Active
-
2021
- 2021-10-25 HU HUS2100046C patent/HUS2100046I1/hu unknown
- 2021-10-27 NL NL301139C patent/NL301139I2/nl unknown
- 2021-11-05 FR FR21C1051C patent/FR21C1051I2/fr active Active
- 2021-11-26 LT LTPA2021530C patent/LTC1968948I2/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301139I2 (nl) | Selumetinibwaterstofsulfaat, desgewenst in watervrije vorm of in de vorm van een solvaat | |
| NL301150I2 (nl) | setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301049I1 (nl) | Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL300946I2 (nl) | Brexpiprazole, desgewenst in de vorm van een zout | |
| NL301067I2 (nl) | Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat | |
| GB0721285D0 (en) | Method for tomographic inversion by matrix transformation | |
| IL184175A (en) | Sulfonyl pyrrolidines, method for producing the same and their use as drugs | |
| DK1730327T3 (da) | Dampelektrolyse | |
| ITMI20052085A1 (it) | Tutore ambidestro per polso provvisto di immobilizzatore del pollice | |
| DE602005027222D1 (de) | Schaumbare zusammensetzung | |
| EP1956065A4 (en) | THINNING / FOAM-EMPOWERING MEDIUM | |
| EP1852499A4 (en) | AGENT PROMOTING NEUROTISATION | |
| FR2887451B1 (fr) | Composition cosmetique anhydre pigmentee | |
| PL1917254T3 (pl) | Sposób wytwarzania amorolfiny | |
| BRPI0923835A2 (pt) | Agente de formação de espuma | |
| IL186851A0 (en) | Styrylsulfonamides, their manufacture and use as pharmaceutical agents | |
| EP1931370A4 (en) | USE OF DES-ASPARTATE-ANGIOTENSIN I | |
| DK1843989T3 (da) | Skumgips | |
| PL1956903T3 (pl) | Zastosowanie produktu chłonnego zawierającego pentano-1,5-diol jako dezodorant | |
| ZA200605597B (en) | Compositions for use with skin | |
| ITTO20050058A1 (it) | Procedimento per la produzione di idrogeno | |
| ITTN20050014A1 (it) | Stallonatore manuale portatile | |
| SE0501726L (sv) | Förtjockare | |
| ITVR20050029A1 (it) | Procedimento per produrre poliuretano | |
| UA12812S (uk) | Футляр для автомобільної аптечки |